Cancer Therapy: Preclinical

Anti-Tumor Activity of Cell-Permeable RUNX3 Protein in Gastric Cancer Cells

Junghee Lim⁴, Tam Duong², Nga Do², Phuong Do², Jaetaek Kim³, Hyuncheol Kim⁴, Wael El-Rifai⁵, H. Earl Ruley⁶ and Daewoong Jo¹²⁵

Authors’ Affiliations

¹ProCell R&D Institute, ProCell Therapeutics, Inc., Seoul, Korea, ²Department of Biomedical Sciences, Chonnam National University Medical School, Kwangju, Korea, ³Department of Internal Medicine, College of Medicine, Chung-Ang University, Seoul, Korea, ⁴Interdisciplinary Program of Integrated Biotechnology, Sogang University, Seoul, Korea, ⁵Departments of Surgery and Cancer Biology, ⁶Department of Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

Running title

Protein Therapy with Cell-Permeable RUNX3

Key words

RUNX3; Macromolecule Transduction Domain; Protein Therapy
Corresponding Author

Dr. Daewoong Jo, Department of Surgery, Vanderbilt University School of Medicine, 1255 MRB IV, 2215B Garland Avenue, Nashville, TN 37232, USA, Tel: 615-322-8207, Fax: 615-322-7852, email: dae-woong.jo@vanderbilt.edu

Grant Support

This work was supported by grant of the Industrial Strategic Technology Development Program (10032101 to D.J.) of Ministry of Knowledge Economy, Republic of Korea.

Disclose any potential conflicts of interest

D.J. was the founding scientist of ProCell Therapeutics, Inc., and is affiliated to Vanderbilt University at present. J.L. is an employee of ProCell Therapeutics, Inc. Hereby; these two authors disclose a financial interest in the company. The other authors disclosed no potential conflicts of interest.

Acknowledgments

We thank Dr. Chris Ko for his critical comment and many young scientists who were involved in the early stage of this study for their technical assistance.
Authors’ Contributors

Conception and design: D. Jo

Development of methodology: J. Lim, T. Duong, N. Do, P. Do, D. Jo

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J. Lim, T. Duong, N. Do, P. Do, D. Jo

Analysis and interpretation of data (e.q., statistical analysis, biostatistics, computational analysis): J. Lim, T. Duong, N. Do, P. Do, J. Kim, H. Kim, W. El-Rifai, H. E. Ruley, D. Jo

Writing, review and/or revision of the manuscripts: H. E. Ruley, D. Jo

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): D. Jo

Study supervision: D. Jo

Abstract count: 248 words

Translational Relevance count: 140 words

Text count: 5,262 words (all text and figure legends)

Total number of figure and table: 6 Figures

Supplementary figure and table: 2 Figures and 1 Table

References: 35
Abstract

**Purpose:** Gastric cancer is a leading cause of cancer death worldwide. Limited therapeutic options highlight the need to understand the molecular changes responsible for the disease and to develop therapies based on this understanding. The goal of this study was to develop cell-permeable (CP-) forms of the RUNT-related transcription factor 3, RUNX3—a candidate tumor suppressor implicated in gastric and other epithelial cancers—to study the therapeutic potential of RUNX3 in the treatment of gastric cancer.

**Experimental Design:** We developed novel macromolecule transduction domains (MTDs) which were tested for the ability to promote protein uptake by mammalian cells and tissues and used to deliver of biologically active RUNX3 into human gastric cancer cells. The therapeutic potential CP-RUNX3 was tested in the NCI-N87 human tumor xenograft animal model.

**Results:** RUNX3 fusion proteins, HM57R and HM85R, containing hydrophobic MTDs enter gastric cancer cells and suppress cell phenotypes (e.g. cell cycle progression, wounded monolayer healing and survival) and induce changes in biomarker expression (e.g. p21^Waf1 and VEGF) consistent with previously described effects of RUNX3 on TGF-β signaling. CP-RUNX3 also suppressed the growth of subcutaneous human gastric tumor xenografts. The therapeutic response was comparable to studies augmenting RUNX3 gene expression in tumor cell lines; however, the protein was most active when administered locally, rather than systemically (i.e.,
Conclusions: These results provide further evidence that RUNX3 can function as a tumor suppressor and suggest that practical methods to augment RUNX3 function could be useful in treating some types of gastric cancer.
Translational Relevance

Advances in understanding the molecular changes responsible for gastric cancer etiology and progression are expected to improve disease diagnosis and treatment. RUNX3 has been implicated as a tumor suppressor gene in gastric cancers; however, this claim is controversial. Using macromolecule intracellular transduction technology, we developed the first cell-permeable (CP-) RUNX3 protein which suppressed cell phenotypes and induced changes in biomarker expression consistent with previously described effects of RUNX3 on TGF-β signaling. The protein also suppressed the growth of human gastric tumors in a mouse xenograft model. These results are consistent with the idea that RUNX3 can function as a tumor suppressor in gastric cancer. Gastric cancer is a leading cause of cancer death; however, only limited therapeutic options are available for tumors not cured by surgical resection. The present study illustrates the use of protein-based therapies to target gastric cancer.
Introduction

Gastric cancer is the most common cancer in Asian countries (e.g., Korea, Japan) and a leading cause of cancer death worldwide, provoking considerable effort to understand the pathogenesis of the disease and to develop improved methods for diagnosis and treatment (1, 2). Gastric tumors arise by multiple etiologies, including an intestinal type that emerges through a metaplasia-dysplasia-carcinoma sequence in which inflammatory responses to H. pylori infection play an initiating role and a diffuse type that arise without clearly defined precursor lesions or etiology. Therapeutic options are limited for gastric cancers not cured by surgical resection, and over-all 5-year survival rates are in the range of 30% (1). As a consequence, there is considerable interest in characterizing the molecular changes responsible for tumor type and grade to better predict disease outcome and possibly, to inform individualized therapies (2).

RUNT-related transcription factor 3 (RUNX3) has been implicated as a tumor suppressor gene in gastric cancers (3) as well as a variety of malignancies (4). Runx3 knockout mice develop gastric hyperplasia and tumors, associated with reduced levels of apoptosis, altered cellular responses to TGF-β (5) and changes in the cyclin dependent kinase inhibitor p21Waf1 and vascular endothelial growth factor (VEGF) expression consistent with enhanced proliferation and angiogenesis, respectively (6, 7). Reductions in RUNX3 expression have been attributed to promoter hypermethylation (8), loss of heterozygosity and protein mislocalization (9) and
correlate with poor prognosis (10-13). Conversely, enforced RUNX3 expression suppresses the proliferation and tumorigenicity of gastric cancer cell lines (3, 7, 10).

However, other studies have challenged the concept that RUNX3 functions directly as a tumor suppressor in gastric cancer (14-17). The murine gene does not appear to be expressed in epithelial cells of the developing or adult gastrointestinal tract (16) and therefore cannot exert cell-intrinsic tumor suppressing effects under normal, steady-state conditions. The gastric hyperplasia observed in Runx3 knockout mice may be a secondary consequence of autoimmune colitis (14), a common consequence of impaired TGF-β signaling in T lymphocytes (18-20). It remains to be determined if RUNX3 is expressed in normal human gut epithelium, although the absence of such expression does not preclude a tumor suppressive role, assuming RUNX3 is induced in response to malignant change. This could also account for low levels of RUNX3 expression observed in some gastric cancer cell lines.

In the present report, we investigated the use of macromolecule intracellular transduction technology (MITT) to deliver biologically active RUNX3 protein into gastric cancer cells, grown both in culture and as tumor xenografts. MITT was used previously to deliver peptides and proteins to a variety of tissues (notably liver, lung, pancreas and lymphoid tissues), resulting in dramatic protection against lethal inflammatory diseases (21-25), suppression of pulmonary metastases (26) and inhibition of subcutaneous tumor xenografts (27). The technology exploits the ability of hydrophobic macromolecule transduction domains (MTDs) to
promote bidirectional transfer of peptides and proteins across the plasma membrane (27-29). By contrast, cationic protein transduction domains (PTDs, e.g. those derived from HIV Tat and Antennapedia) enhance protein uptake predominately through absorptive endocytosis and macropinocytosis, which sequester significant amounts of protein into membrane-bound and endosomal compartments and limit cell-to-cell spread within tissues (30, 31). However, cellular uptake and systemic delivery are both heavily influenced by the cargo, such that the utility of any protein transduction approach must be investigated on a case-by-case basis (30-32). In the present study we developed a cell-permeable RUNX3 protein to examine the direct effects of RUNX3 in living cells under non steady-state conditions and to investigate the feasibility of using RUNX3 as a protein-based therapy for gastric cancer.
Materials and Methods

Expression and purification of MTD fusion proteins

MTD13, MTD57, MTD85 and MTD108 were derived from signal sequences from NP_639877, CAD0547.1, NP_629842.1, and NP_003842 respectively, as previously described (26, 27). Histidine-tagged fusion proteins containing EGFP or the full-length 46 kDa RUNX3 protein (33) and MTD13, MTD57, MTD85, MTD108, the FGF4 MTS (M_m, AAVLPVLLAAP) or a random sequence (S, SANVEPLERL) were cloned into pET-28a(+) (Novagen, Darmstadt, Germany) and expressed in *E. coli* BL21-CodonPlus (DE3) cells.

Histidine-tagged recombinant proteins were purified on a Qiagen Ni^{2+} affinity resin under denaturing conditions and refolded by dialysis against 0.55 M guanidine HCl, 0.44 M L-arginine, 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 100 mM NDSB, 2 mM reduced glutathione, and 0.2 mM oxidized glutathione for 48 hrs at 4°C and then changed to RPMI 1640 medium. Proteins were quantified by the Bradford method (Bio-Rad), were aliquoted, and stored at -20°C. The purified proteins were judged to have minimum levels of endotoxin as assessed by the limulus amebocyte lysate (LAL) assay (Associates of Cape Cod, Inc.). Recombinant proteins were named using the following convention: H, R and M stand for the His tag; RUNX3 and MTD, respectively. Histidine-tagged recombinant proteins were HR (His-RUNX3), HM_mR (His-MTS-RUNX3), HRM_m (His-RUNX3-MTS), HM_mRM_m (His-MTS-RUNX3-MTS), HM_{57}R (His-MTD57-RUNX3), HM_{85}R (His-MTD85-RUNX3)
Protein uptake and tissue distribution

Recombinant proteins were conjugated to 5/6-FITC and uptake by cultured RAW 264.7 and NIH3T3 cells were assessed as described previously (26, 27). Briefly, the cells were treated with 10 μM FITC-labeled proteins for 1 hr at 37°C, washed with cold PBS three times, and treated with proteinase K (10 μg/ml) for 20 min at 37 °C to remove cell-surface bound proteins. Protein uptake was quantified by flow cytometry (FACSCalibur; BD Biosciences). Balb/c mice (6 weeks old, female) were injected intraperitoneally (300 μg/head) with FITC only or FITC-conjugated proteins. After 2 hrs, the liver, kidney, spleen, lung, heart and brain were isolated, washed with an O.C.T. compound (Sakura) and frozen on dry ice. Cryosections (15 μm) were analyzed by fluorescence microscopy.

Western blot analysis

Human gastric cancer cell lines MKN28 and NCI-N87 (Korean Cell Line Bank, Seoul, Korea) were cultured in RPMI 1640 medium and maintained at 37°C in an atmosphere containing 5% CO2. 5 x 10^6 cells (plated the previous day) were incubated with or without 2 ng/ml TGF-β for 24 hrs and then treated with 10 μM of RUNX3 proteins (HR, HMmR, HRMm, HMmRMm, HM57R and HM85R) for 1 hr. Cell were lysed either immediately (Rb phosphorylation) or after 12 hrs (p21Waf1, p27Kip1, PCNA, cleaved Caspase-3, Cyclin A, Cyclin E and VEGF expression)
in 200 μl ice cold lysis buffer (20 mM HEPES, pH 7.2, 1% Triton-X, 10% glycerol) and centrifuged at 12,000 rpm for 20 min at 4°C. Supernatants were assayed for protein content (Bio-Rad Bradford Protein Assay) and stored at -80°C until use. The antibodies for p21\textsuperscript{Waf1} and cleaved Caspase-3 were from Cell Signaling Technology, and the antibodies for p27\textsuperscript{Kip1}, PCNA, Cyclin A, Cyclin E, phospho-Rb (Ser807/811) and VEGF were from Santa Cruz Biotechnology. The secondary antibody was goat anti-mouse IgG-HRP (Santa Cruz Biotechnology).

**Wound healing assay**

MKN28 and NCI-N87 cells were incubated with TGF-β (2 ng/ml) for 24 hrs and washed extensively with PBS. The cells were then treated with 10 μM HR, HM\textsubscript{m}RM\textsubscript{m}, HM\textsubscript{57}R or HM\textsubscript{85}R for 1 hr in serum-free medium. The cells were washed twice with PBS, and the monolayer at the center of the well was “wounded” by scraping with a pipette tip. Cell proliferation and/or migration was observed by phase contrast microscopy.

**Effects of CP-RUNX3 on cell proliferation and survival**

NCI-N87 cells were treated with 5 μM HR, HM\textsubscript{m}RM\textsubscript{m}, HM\textsubscript{57}R or HM\textsubscript{85}R for 1 hr at 37°C and analyzed for changes in DNA content and cell survival. To monitor changes in DNA content, the cells were washed twice with cold PBS, resuspended in 200 μl cold PBS and fixed by gradual addition of 4 ml cold 70% ethanol, washed twice with cold PBS and re-suspended in PI.
master mix (40 μg/ml propidium iodide, 100 μg/ml DNase-free RNase in PBS) at a final cell density of 0.5 × 10^6 cell/ml. The cell mixtures were incubated at 37°C for 30 min prior to analysis by flow cytometry. Changes in cell viability were determined by using the sulforhodamine B (SRB) assay (34) after treating cells with recombinant proteins for 72 hrs. The cells were fixed and stained by the addition of 0.4% (w/v) SRB in 1% acetic acid solution. Loss of cell viability was assessed by increased SRB staining as determined by increased absorbance at 540 nM.

Apoptotic and necrotic cells were analyzed using an annexin-V assay kit (BD Biosciences). Briefly, treated cells were washed twice with cold PBS and re-suspended in binding buffer (10 mM HEPEPS, 140 mM NaCl, 25 mM CaCl₂, pH 7.4) at a concentration of 1 × 10^6 cells/ml. The cells were then treated with a solution containing FITC-labeled annexin-V and PI solution, followed by analysis on a FACSCalibur (BD Biosciences).

**Xenograft tumor model**

Five-week old, immune deficient Balb/c nu/nu mice (Central Lab. Animal Inc., Seoul, Korea) were subdivided into 4 groups of 5 mice each. NCI-N87 cells were administered to the left upper back of the mouse via subcutaneous (SC) injection at a concentration of 1 × 10^7 cells/ml. Once the tumor size was measured as 60-80 mm³ (width² × length × 0.5), the protein (HR, HM₅₇R or HM₈₅R) or diluent (PBS) was administered daily for 21 days (100 μg/mouse, 5 mg/kg, 100 μl) via subcutaneous injection at the left upper back of the mouse, at sites adjacent
to the tumor. Tumor size was monitored by measuring the longest (length) and shortest dimensions (width) once a day with a dial caliper, and tumor volume was calculated as \( \text{width}^2 \times \text{length} \times 0.5 \). Alternatively, mice (\( n = 10/\text{group} \)) were treated with proteins via daily intravenous injection in the lateral tail vein for 21 days (300 \( \mu \text{g/mouse}, 15 \text{ mg/kg}, 300 \mu \text{l} \)).

**Histological analysis of protein expression and apoptosis**

\( p21^{\text{Waf1}} \) and VEGF expression in tumors was assessed by immunohistochemical staining of paraffin-embedded sections 21 and 35 days after starting protein therapy as described previously (26, 27). Tissue sections were stained with anti-\( p21^{\text{Waf1}} \) (Cell Signaling Technology) or VEGF (Santa Cruz Biotechnology) primary antibodies and with goat anti-mouse IgG-HRP (Biogenex) secondary antibody and counter-stained with hematoxylin. Apoptosis in tumor sections was analyzed 21 days after starting protein therapy by the \textit{In situ} Cell Death Detection Kit, TMR red (Roche) and ApopTag Red \textit{In Situ} Apoptosis Detection Kit (Chemicon, Billerica) as specified by the suppliers. Reverse-transcription PCR (RT-PCR) analysis was performed using total RNA isolated from tumor tissues at day 21.

**Statistical analysis**

All experimental data obtained from cultured cells are expressed as the means ± S.D. Statistical significance was evaluated using a one-tailed Student’s \( t \)-test. For animal testing,
paired t-tests for comparisons between and within groups were used to determine the significance of the differences in tumor volume \textit{in vivo}. Statistical significance was established at $p < 0.05$. 
Results

Development of cell-permeable RUNX3 proteins

MTD57 and MTD85 were identified from a screen of 1,500 potential hydrophobic signal peptides for sequences with protein transduction activity as assessed using an EGFP reporter protein. Sequences spanning amino acids 1-23 of CAD0547.1 and 20-42 of NP_629842.1 were subsequently modified to LIALLAAPLA and LLAAAAALLLA, respectively (Supplementary Table S1). Both peptides promoted greater cellular uptake of an EGFP cargo protein by cultured NIH3T3 cells than the reference membrane translocating sequence, MTS (M_m), derived from the hydrophobic signal peptide of fibroblast growth factor 4 (FGF4) (Supplementary Fig. S1A). Their relative cell permeability to the FGF4-MTS was 1.8 and 4.8 fold (Supplementary Fig. S1B). Finally, MTD57, MTD85, and the FGF4 MTS all enhanced the systemic delivery of EGFP proteins to a variety of tissues, including liver, kidney, spleen, lung, heart and brain after intraperitoneal injection, although the HM_85E and HM_mE showed greater tissue distribution 48 hrs post-injection than HM_57E (Supplementary Fig. S1C). By contrast, HSE, an EGFP protein containing a random sequence (Supplementary Fig. S1C) instead of an MTD did not accumulate in distal tissues.

RUNX3 fusion proteins containing MTD57, MTD85, and the FGF4 MTS along with a 6x histidine tag and nuclear localization signal (NLS) from SV40 large T antigen (Fig. 1A) were expressed in E. coli DE3 cells, purified under denaturing conditions (Fig. 1B) and refolded, with
yields of soluble protein ranging from 2 to 36 mg/L (Fig. 1A). The NLS sequence was included first, to enhance nuclear localization (based on our experience with other CP-Proteins) given reports that RUNX3, which is a nuclear transcription factor, may be inactivated by processes in tumor cells that cause the protein to localize to the cytoplasm (9) and second to enhance the solubility of MTD containing recombinant proteins.

To examine protein uptake, the recombinant proteins were conjugated to 5/6-FITC and incubated with NIH3T3 cells at (10 mM for 1 hr at 37°C). The cells were washed three times with ice-cold PBS, treated with proteinase K (10 mg/ml for 20 min at 37°C) to remove surface-bound proteins, nuclei were counter-stained with 1 mg/ml propidium iodide and internalized proteins were visualized by confocal laser scanning microscopy (Fig. 2A). RUNX3 proteins containing either MTD57 (HM57R) or MTD85 (HM85R) or the FGF4 MTS (HM,m, HRM,m and HM,mRM,m) efficiently entered cells and were localized to various extents in both the nucleus and cytoplasm. By contrast, a RUNX3 protein (HR) containing only the 6xHis and NLS sequences did not appear to enter cells (Fig. 2A). While HM57R and HM85R both entered cells, HM85R displayed more uniform cellular distribution, and the protein was more soluble. As with the EGFP cargo, protein uptake of HM85R by RAW264.7 cells was also very efficient (Fig. 2B). In addition, MTD85
enhanced the systemic delivery of RUNX3 protein to a variety of tissues (liver, kidney, spleen, lung, heart and, to a lesser extent, brain) after intraperitoneal injection (Fig. 2C).

RUNX3 proteins with MTD13 (LAAAALAVLPL) and MTD108 (ALLAALLAP) in place of MTDs 57 and 85 were also evaluated but the proteins were less soluble, produced lower yields when expressed in E. coli and entered cells less efficiently (data not shown); therefore, these proteins were not evaluated further.

**Biological activities of cell-permeable RUNX3**

RUNX3 participates in TGF-β signaling by interacting with SMADs to influence the TGF-β regulated gene expression and inhibit cell cycle progression. We therefore examined the effects of CP-RUNX3 on cell proliferation and associated biomarker expression in human gastric cancer cell lines, NCI-N87 and MKN28. NCI-N87 cells were incubated in normal culture media either lacking or containing TGF-β and treated with the recombinant RUNX3 proteins fused to either a reference MTS (HMmRMm), an MTD (HM57R and HM85R) or a RUNX3 protein lacking an MTD (HR) (Fig. 3A). While TGF-β alone produced only modest changes in biomarker expression (cell only in Fig. 3A), the cell permeable forms of RUNX3 suppressed the Cyclin A, Cyclin E, and VEGF expression and Rb phosphorylation, as assessed by Western blotting. Changes in biomarker expression were greater in the presence than absence of TGF-β, and the greatest suppression was observed with HM85R, followed by HM57R, while HMmRMm produced the
smallest effect. Similar results were obtained in the presence of TGF-β using another gastric cancer cell line (MKN28), and the cell-permeable RUNX3 proteins also enhanced the expression of the cyclin-dependent kinase inhibitors, p21\textsuperscript{Waf1} and p27\textsuperscript{Kip1} and suppressed the expression of proliferating cell nuclear antigen, PCNA (Fig. 3B). Finally, HM\textsubscript{85}R stimulated Caspase-3 cleavage, a pro-apoptotic marker (Fig. 3B).

We next examined the ability of cell-permeable RUNX3 to influence cell cycle re-entry, migration or proliferation as assessed by a monolayer wounding assay. Gastric cancer cells MKN28 and NCI-N87 pretreated with 2ng/ml TGF-β were treated with recombinant proteins for 1 hr, the monolayers were wounded, and cell migration/proliferation in the wound was monitored (Fig. 3C, left panel) and analyzed statistically (Fig. 3C, right panel) after 48 hrs. All CP-RUNX3 proteins tested (HM\textsubscript{m}RM\textsubscript{m}, HM\textsubscript{57}R and HM\textsubscript{85}R) suppressed repopulation of the wounded monolayer; however, HM\textsubscript{85}R produced the greatest inhibitory effect in both cell lines by 88% in MKN28 and 82% in NCI-N87 cells, respectively. In light of these results, HM\textsubscript{85}R was selected as the most active CP-RUNX3 protein for further evaluation as a potential anti-tumor agent.

Activation of Caspase-3 in HM\textsubscript{85}R-treated cancer cells led us to examine the effects of CP-RUNX3 on apoptosis and necrosis. The effects of treating of NCI-N87 cells with HM\textsubscript{85}R after 72 hrs included substantial loss of cell viability as assessed by the sulforhodamine B (SRB) assay (Fig. 4A), enhanced annexin-V staining (Fig. 4B) and accumulation of cells with less than G\textsubscript{1} DNA content, which occurred primarily at the expense of cells with a G\textsubscript{1} DNA content (Fig. 4C).
However, most of the cells with enhanced annexin-V staining also stained with propidium iodide (Fig. 4D), indicative of either late apoptosis or necrotic cell death. The lack of annexin-V single-positive cells, even at early time points, suggests that the loss of cell viability induced by HM$_{85}$R results from necrotic cell death. The effect was more pronounced in NCI-N87 cells that had higher basal levels of necrosis than MKN28 cells (data not shown). Unlike the gastric cancer cell lines, CP-RUNX3 did not appear to be toxic to NIH3T3 cells (data not shown).

**Anti-tumor activity of cell-permeable RUNX3**

We next assessed the anti-tumor activity of CP-RUNX3 against human cancer xenografts. NCI-N87 cells were injected subcutaneously into nude mice, tumors were allowed to grow in size to 60–80 mm$^3$, and then the mice were injected subcutaneously near the tumors with 5 mg/kg recombinant RUNX3 proteins (HR, HM$_{57}$R or HM$_{85}$R) or diluent (PBS) every day for 3 weeks. Mice were observed for an additional 2 weeks after treatments ended (Fig. 5A). HM$_{57}$R and HM$_{85}$R significantly suppressed the tumor growth ($p < 0.05$) during the treatment phase. However, once treatment stopped sustained anti-tumor activity was observed only in HM$_{85}$R-treated mice (87% inhibition at day 21; 74% at day 35, respectively) whereas, the growth of HM$_{57}$R-treated tumors increased, matching the rates observed in control mice. Differences among the tumors from different treatment groups were apparent by external examination (Fig. 5B) and tumors weight (Fig. 5C). While tumor growth was also reduced in mice treated with the HR control
protein, which lacks a MTD sequence, the effect was not significant.

CP-RUNX3 was also tested for anti-tumor activity following systemic rather than local delivery (Fig. 5D). Tumor bearing mice were prepared as before and were injected intravenously daily for three weeks with (i) 15 mg/kg HM85R; (ii) two control proteins: HR, RUNX3 lacking an MTD sequence, and HM85E, which contains EGFP instead of the RUNX3 sequence; or (iii) buffer alone. Although HM85E displayed anti-tumor activity as compared to the control proteins, the effects were relatively modest (70% inhibition at day 21).

Anti-tumor activity of HM85R was accompanied by apoptosis/necrosis as visualized by TUNEL and ApopTag staining of tumor sections analyzed three weeks after treatment (Fig. 6A), and by changes in biomarker expression linked to RUNX3 signaling, including enhanced levels of p21Waf1 (Fig. 6B, upper panel) and lower levels of VEGF (Fig. 6B, lower panel), CCNE (cyclin E2), FOS and JUN (Fig. 6C) at day 21. Loss of p21Waf1 expression persisted in HM85R-treated tumors at day 35 (Fig. 6D); whereas, VEGF levels returned to normal by day 35 (data not shown). By contrast, tumor biomarker expression was not affected in mice treated with the HR control protein, which lacks a MTD sequence. Finally, all of the proteins tested appeared to be well tolerated as assessed by external appearance, activity level and body weight (Supplementary Fig. S2).
Discussion

The present study investigated the use of macromolecule intracellular transduction technology (MITT) to deliver biologically active RUNX3 protein into gastric cancer cells both in vitro and in vivo. Proteins engineered to enter cells suppressed cell proliferation, wound healing and survival, consistent with its role as a tumor suppressor. Moreover, the cell-permeable RUNX3 induced changes in biomarker expression, notably p21^{Waf1} and VEGF, consistent with its known role in TFG-β signaling. The protein also enhanced apoptotic/necrotic cell death of NCI-N87 cells, in vitro and apoptosis/necrosis in NCI-N87 tumor xenografts, with changes in p21^{Waf1} and VEGF expression consistent with a direct effect on tumor cells.

The present study used two new macromolecule transduction domains, MTD57 and MTD85, to deliver RUNX3 proteins into cultured cells and tumors. These MTD sequences were developed by a process in which predicted leader peptides were first tested for their ability to promote uptake of an EGFP reporter protein by cultured cells, and the sequences were subsequently modified to eliminate charged amino acids, increase the predicted α-helical content, and limit the number of consecutive hydrophobic residues. MTD85 was observed to be a more efficient delivery vehicle than MTD57 as assessed with EGFP and RUNX3 protein cargoes. Consistent with greater protein uptake, MTD85 modified RUNX3 proteins had greater biological activity both in vitro and in vivo. Computer models also suggest MTD85 has a
greater α-helical structure than MTD57 (Supplementary Table S1), a feature associated with enhanced protein uptake (29). However, further study will be required to determine protein sequences and/or structures required for optimal protein delivery.

In principle, protein-based therapeutics offers a way to control biochemical processes in living cells under non steady-state conditions and with fewer off target effects than conventional small molecule therapeutics. In practice, systemic protein delivery in animals has proven difficult due to poor tissue penetration and rapid clearance (30, 31). Some success has been achieved using sequences derived from hydrophobic signal peptides to deliver biologically active peptides and proteins to a variety of tissues (including liver, lung, pancreas and lymphoid tissues). Striking therapeutic benefits have been reported using a small peptide to protect against otherwise lethal inflammatory responses (21, 23-25). Therapeutic benefits have also been achieved using larger cell-permeable proteins including: (i) suppressor of cytokine signaling 3 (SOCS3) to protect animals against lethal inflammation (22), (ii) the NM23 metastasis suppressor to inhibit the seeding and growth of pulmonary metastases (26) and (iii) the cyclin-dependent kinase inhibitor, p18INK4c, to inhibit the growth of tumor xenografts (27). Since the practical development of cell permeable proteins has a large empirical component, the present study is part of a larger effort to understand the variables that might predict whether a given protein can be delivered in biologically active form into mammalian cells and tissues. In addition, we wanted to determine if CP-RUNX3 had activities consistent with tumor suppression
and test the feasibility of using RUNX3 as a protein-based therapy to treat gastric cancer, a cancer for which no effective therapies currently exist (35).

The anti-tumor activity of CP-RUNX3 was comparable to that associated with augmenting RUNX3 gene expression in tumor cell lines. This is despite the fact that subcutaneous tumors, due to limited vascularization, provide a challenging test of in vivo protein delivery and uptake. Thus, the activity of CP-RUNX3 approached the expected theoretical limit as determined by cell-intrinsic RUNX3 biology—consistent with the idea that RUNX3 can function as a tumor suppressor in gastric cancer. However, this interpretation carries several caveats. First, although mice tolerated high levels of RUNX3 protein without weight loss or obvious adverse effects, the tumor-specific effects of exogenous CP-RUNX3 are potentially non-physiological, since protein levels delivered by transduction are higher [compare levels of CP-RUNX3 in cells and tissues, Figure 2, with levels of endogenous RUNX3 reported elsewhere (9, 10)]. Moreover the influx of CP-RUNX3 is relatively rapid (within 60 min)—a greater rate of change than would be expected in normal cells undergoing cell differentiation or oncogenic transformation. Second, although RUNX3 directly targeted xenografted tumor cells as assessed by changes in p21Waf1 and VEGF expression, we cannot exclude the possibility CP-RUNX3 also targets other cells such as vascular endothelium that influence tumor growth and/or survival in the subcutaneous niche.

The anti-tumor activity of CP-RUNX3 fell short of that achieved by either CP-p18INK4a or
CP-MN23, which target cell cycle and metastasis, respectively (26, 27). Moreover, CP-p18\textsuperscript{INK4c} and CP-MN23 produced prolonged therapeutic effects when administered systemically (i.e. by IV injection), whereas, CP-RUNX3 was most active when administered subcutaneously in regions surrounding the tumors. Therefore, further therapeutic development of CP-RUNX3 will require formulations with improved bioavailability when administered systemically, e.g, by using different MTDs or smaller, biologically active RUNX3 domain(s). A full evaluation will require testing CP-RUNX3, both individually and in combination with other agents, and with a variety of cancer models.
Figure legends

**Figure 1. Structure and expression of MTD-RUNX3 fusion proteins.** RUNX3 fusion proteins were expressed and purified. A, Structure of His-tagged RUNX3 proteins containing MTD57 or MTD85. H, Mm, M57, M85 and R refer to 6xHis tag ( ), the FGF4 MTS ( ), MTD57 ( ) or MTD85 ( ) and RUNX3 ( ), respectively. A nuclear localization sequence from SV40 T antigen is also shown ( ). The size (number of amino acids) and yield (mg/L) of each recombinant protein is indicated. B, Protein Expression in *E. coli.* SDS PAGE analysis of cell lysates before (-) and after (+) induction with IPTG and aliquots of Ni²⁺ affinity purified proteins. The mobility of recombinant RUNX3 proteins is indicated. Solubility was scored on a 4 point scale ranging from highly soluble proteins with little tendency to precipitate (****) to largely insoluble proteins (*).

**Figure 2. Efficient MTD-mediated RUNX3 protein delivery into cells and tissues.** CP-RUNX3 proteins efficiently entered cells and were localized in both the nucleus and cytoplasm. HM₈₅R was systemically delivered to a variety of tissues. A, RUNX3 protein uptake by NIH3T3 cells. NIH3T3 cells were incubated with 10 μM FITC-conjugated recombinant MTD-RUNX3 proteins, an equimolar concentration of unconjugated FITC (FITC only) or vehicle (culture medium RPMI 1640) for 1 hr, were washed and treated with proteinase K to remove non-internalized protein and visualized by fluorescence confocal laser scanning microscopy. B, Uptake of MTD-RUNX3
protein (HM_{85}R) by RAW264.7 cells. Cells were exposed to 10 μM of the FITC conjugated RUNX3 proteins containing MTD85 (HM_{85}R, red) or lacking MTD (HR, blue), or 10 μM of FITC alone (black thin line) for 1 hr, treated to remove cell-associated but non-internalized protein and analyzed by flow cytometry. C, Systemic RUNX3 protein delivery to murine tissues. Cryosections (15 μm) of saline-perfused organs were prepared from mice 2 hrs after intraperitoneal injection of 20 μg FITC or 300 μg FITC-labeled RUNX3 proteins with (HM_{85}R) and without (HR) the MTD85 sequence. Uptake (A) and tissue distribution (B) of the recombinant proteins (green staining) was assessed by fluorescence microscopy.

**Figure 3.** CP-RUNX3 protein induces changes in biomarker expression and suppresses cell phenotypes--cell cycle re-entry and wound healing--in the presence of TGF-β. CP-RUNX3 suppressed the Cyclin A, Cyclin E, and VEGF expression and Rb phosphorylation, enhanced the expression of the p21^{Waf1} and p27^{Kip1}, suppressed the expression of PCNA, and stimulated Caspase-3 cleavage in gastric cancer cells in the presence of TGF-β. CP-RUNX3 proteins also suppressed proliferation of cancer cells. A and B, Western blot analyses. NCI-N87 (A) or MKN28 cells (B) incubated without (-) or with (+) TGF-β (2 ng/ml) for 24 hrs and treated for 1 hr with 10 μM recombinant RUNX3 proteins fused to FGF4-derived MTS (HM_{m}R, HR_{m} or HM_{m}RM_{m}), MTD57 (HM_{57}R), MTD85 (HM_{85}R) or no MTD (HR). Cells were treated with proteins in serum-free media, and lysed immediately to analyze Rb phosphorylation or incubated an
additional 12 hrs in serum-containing media to detect cleaved Caspase-3, p21<sup>Waf1</sup>, p27<sup>Kip1</sup>, PCNA, Cyclin A, Cyclin E and VEGF. C, Wound-healing assay. Cell monolayers were incubated with TGF-β (2 ng/ml) for 24 hrs, treated with HR or HM<sub>85R</sub> proteins for 1 hr in serum-free media, visualized and (left panel) and analyzed statistically (right panel) after an additional 48 hrs in normal growth media. Photographed data shown here is representative of three independent assays. The data are presented as means ± s.d. (n = 3), * p < 0.01 as determined by a Student’s unpaired t-test.

**Figure 4.** Cell-permeable RUNX3 induces apoptosis/necrosis. HM<sub>85R</sub>-treatment induced substantial loss of cell viability induced by apoptosis/necrosis in the gastric cancer cells. A, Sulforhodamine B (SRB) binding assay. NCI-N87 cells were treated for 1 hr with 10 µM HR or HM<sub>85R</sub> proteins and cell viability was assessed 72 hrs later by the SRB binding assay. Loss of cell viability induced by CP-RUNX3 (HM<sub>85R</sub>) and not control RUNX3 protein without the MTD sequence (HR) is indicated by reduced staining (A<sub>540</sub>). B-D, Apoptosis/necrosis assays. NCI-N87 cells were treated for 1 hr with 10 µM HR or HM<sub>85R</sub> proteins and at the indicated times the cells were analyzed for annexin-V staining (B); DNA content (C), flow cytometry of cells stained with propidium iodide; and apoptosis/necrosis (D), flow cytometry of cells stained with both propidium iodide and annexin V. Apoptotic/necrotic cells induced by CP-RUNX3 (HM<sub>85R</sub>) are indicated by accumulation of cells with less than a G<sub>1</sub> DNA content (B), by increased annexin V.
staining (C) and by accumulation of cells staining with both PI and annexin V (D).

**Figure 5. CP-RUNX3 protein suppresses the growth of human gastric tumors in a mouse xenograft model.** HM<sub>85R</sub> significantly suppressed tumor growth (by 87% 21 days after subcutaneous administration) with sustained anti-tumor activity (74% at day 35). Intravenously administered HM<sub>85R</sub> was less active than subcutaneously administered protein (70% at day 21). A, Suppression of tumors induced by subcutaneous injection of NCI-N87 human gastric cancer cells. After tumors reached a size of 60-80 mm<sup>3</sup> (start) the mice were injected daily (subcutaneously near the tumor) for three weeks with diluent alone (black) or with 100 µg HR (blue), HM<sub>57R</sub> (green) or HM<sub>85R</sub> (red). Tumor growth was suppressed to varying degrees after protein therapy ended (stop). * p < 0.05 as determined by Student’s t-test. Efficient tumor inhibition, up to 87%, required MTD sequences. B, External appearance of tumor bearing mice. Representative mice treated with diluent alone or with HM<sub>85R</sub> were photographed on day 1 and 21 after starting protein therapy. Differences in tumor growth are apparent by external examination. C, Representative tumor appearance and weight. Tumors dissected 21 days after treatment with diluent, HR, HM<sub>57R</sub> and HM<sub>85R</sub> were photographed and weighed. * p < 0.05 as determined by Student’s t-test. D, Suppression of tumor growth by intravenous injection of CP-RUNX3. Tumor-bearing nude mice induced by subcutaneous injection of NCI-N87 human gastric cancer cells were treated intravenously for three weeks with
diluent alone (black) or with 300 µg HR (green), HM85E (blue) or HM85R (red). * $p < 0.05$ as determined by Student’s $t$-test. Tumor growth was inhibited by 70% (day 21) by CP-RUNX3 (HM85R) not by proteins containing a neutral gene (EGFP, HM85E) or lacking the MTD sequence (HR).

**Figure 6. Anti-tumor activity of CP-RUNX3 proteins.** HM85R induced apoptosis/necrosis in tumors accompanied by changes in biomarker expression linked to RUNX3/TGF-β signaling. A, CP-RUNX3 induces tumor cell apoptosis. Sections from paraffin imbedded tumors were prepared after treatment for 3 weeks after protein therapy ended (day 21), and apoptotic cells were visualized by Apop Tag and TUNNEL staining. B and D, Immunohistochemistry. C, Reverse transcriptase PCR. HM85R-induced changes in biomarker expression in tumor xenografts. Tumor sections from mice treated daily for 3 weeks with diluent alone, or with 100 µg of either HR or HM85R were sectioned and immunostained with antibodies against p21$^{\text{Waf1}}$ or VEGF. Gene expression profile of the tumors obtained from mice treated with HR or HM85R compared to diluent. D, Loss of p21$^{\text{Waf1}}$ expression persisted in HM85R-treated tumors at day 35.
References


Figure 3

### A

<table>
<thead>
<tr>
<th>TGF-β (2 ng/ml)</th>
<th>-</th>
<th>+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proteins (10 μM)</td>
<td>Cell only</td>
<td>HR</td>
</tr>
<tr>
<td>Cyclin A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclin E</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VEGF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-Rb</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### B

<table>
<thead>
<tr>
<th>TGF-β (2 ng/ml)</th>
<th>+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proteins (10 μM)</td>
<td>Cell only</td>
</tr>
<tr>
<td>Cleaved caspase-3</td>
<td></td>
</tr>
<tr>
<td>Cyclin A</td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
</tr>
<tr>
<td>Cyclin E</td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
</tr>
<tr>
<td>PCNA</td>
<td></td>
</tr>
<tr>
<td>p21</td>
<td></td>
</tr>
<tr>
<td>p27</td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
</tr>
<tr>
<td>p-Rb</td>
<td></td>
</tr>
<tr>
<td>VEGF</td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
</tr>
</tbody>
</table>

### C

<table>
<thead>
<tr>
<th>Scratched Cells</th>
<th>Cell only</th>
<th>HR</th>
<th>HM&lt;sub&gt;sR&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>MKN28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCI-N87</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

% Healing

- **Cell only**
- **HR**
- **HM<sub>sR</sub>**

* Sign indicates statistically significant difference.
Figure 4

A

\[ A_{560} \]

\begin{align*}
\text{Vehicle} & \quad \text{HR} & \quad \text{HM}_{85}\text{R} \\
\end{align*}

\begin{align*}
\text{Treatment} \\
0 \text{ h} & \quad <1\% & \quad 1.9\% & \quad 1.0\% \\
2 \text{ h} & \quad <1\% & \quad 5.7\% & \quad 25.2\% \\
4 \text{ h} & \quad 1.4\% & \quad 6.1\% & \quad 20.8\% \\
8 \text{ h} & \quad 1.5\% & \quad 32.8\% & \quad 32.8\% \\
\end{align*}

B

\begin{align*}
\text{Vehicle} & \quad \text{HR} & \quad \text{HM}_{85}\text{R} \\
\text{2 h} & \quad 5\% & \quad 10\% & \quad 20\% \\
\text{4 h} & \quad 10\% & \quad 20\% & \quad 30\% \\
\end{align*}

D

\begin{align*}
\text{Cell} & \quad \text{HR} & \quad \text{HM}_{85}\text{R} \\
\text{2 h} & \quad 6.1 & \quad 12.1 & \quad 15.1 \\
\text{4 h} & \quad 10.1 & \quad 9.5 & \quad 33.9 \\
\end{align*}
Figure 5

A. Graph showing tumor volume (mm³) over days after implantation of tumor cells. The graph compares Diluent (n=5), HR (n=5), HM₅₅R (n=5), and HM₆₆R (n=5).

B. Images illustrating relative tumor size at Day 1 (1:1) and Day 21 (3.6:1). Tumor growth rate = 100% : 36%.

C. Images of tumors from different groups: Diluent, HR, HM₅₅R, and HM₆₆R. Tumor weights: Diluent (1.1 ± 0.2 g), HR (1.1 ± 0.2 g), HM₅₅R (0.8 ± 0.1 g), HM₆₆R (0.3 ± 0.04 g).

D. Additional graph showing tumor volume (mm³) over days after implantation of tumor cells.
Figure 6

A

<table>
<thead>
<tr>
<th></th>
<th>Diluent</th>
<th>HR</th>
<th>HM85R</th>
</tr>
</thead>
<tbody>
<tr>
<td>TUNEL</td>
<td><img src="TUNEL_Day21.png" alt="Image" /></td>
<td><img src="TUNEL_HR_Day21.png" alt="Image" /></td>
<td><img src="TUNEL_HM85R_Day21.png" alt="Image" /></td>
</tr>
<tr>
<td>ApopTag</td>
<td><img src="ApopTag_Day21.png" alt="Image" /></td>
<td><img src="ApopTag_HR_Day21.png" alt="Image" /></td>
<td><img src="ApopTag_HM85R_Day21.png" alt="Image" /></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th></th>
<th>Diluent</th>
<th>HR</th>
<th>HM85R</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor</td>
<td><img src="Tumor_Day21.png" alt="Image" /></td>
<td><img src="Tumor_HR_Day21.png" alt="Image" /></td>
<td><img src="Tumor_HM85R_Day21.png" alt="Image" /></td>
</tr>
<tr>
<td>p21</td>
<td><img src="p21_Day21.png" alt="Image" /></td>
<td><img src="p21_HR_Day21.png" alt="Image" /></td>
<td><img src="p21_HM85R_Day21.png" alt="Image" /></td>
</tr>
<tr>
<td>VEGF</td>
<td><img src="VEGF_Day21.png" alt="Image" /></td>
<td><img src="VEGF_HR_Day21.png" alt="Image" /></td>
<td><img src="VEGF_HM85R_Day21.png" alt="Image" /></td>
</tr>
</tbody>
</table>

C

<table>
<thead>
<tr>
<th>Gene</th>
<th>Diluent</th>
<th>HM85E</th>
<th>HR</th>
<th>HM85R</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCNE2</td>
<td><img src="CCNE2_Day35.png" alt="Image" /></td>
<td><img src="CCNE2_HM85E_Day35.png" alt="Image" /></td>
<td><img src="CCNE2_HR_Day35.png" alt="Image" /></td>
<td><img src="CCNE2_HM85R_Day35.png" alt="Image" /></td>
</tr>
<tr>
<td>FOS</td>
<td><img src="FOS_Day35.png" alt="Image" /></td>
<td><img src="FOS_HM85E_Day35.png" alt="Image" /></td>
<td><img src="FOS_HR_Day35.png" alt="Image" /></td>
<td><img src="FOS_HM85R_Day35.png" alt="Image" /></td>
</tr>
<tr>
<td>JUN</td>
<td><img src="JUN_Day35.png" alt="Image" /></td>
<td><img src="JUN_HM85E_Day35.png" alt="Image" /></td>
<td><img src="JUN_HR_Day35.png" alt="Image" /></td>
<td><img src="JUN_HM85R_Day35.png" alt="Image" /></td>
</tr>
<tr>
<td>MRAS</td>
<td><img src="MRAS_Day35.png" alt="Image" /></td>
<td><img src="MRAS_HM85E_Day35.png" alt="Image" /></td>
<td><img src="MRAS_HR_Day35.png" alt="Image" /></td>
<td><img src="MRAS_HM85R_Day35.png" alt="Image" /></td>
</tr>
<tr>
<td>GAPDH</td>
<td><img src="GAPDH_Day35.png" alt="Image" /></td>
<td><img src="GAPDH_HM85E_Day35.png" alt="Image" /></td>
<td><img src="GAPDH_HR_Day35.png" alt="Image" /></td>
<td><img src="GAPDH_HM85R_Day35.png" alt="Image" /></td>
</tr>
</tbody>
</table>

D

<table>
<thead>
<tr>
<th></th>
<th>Diluent</th>
<th>HR</th>
<th>HM85R</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor</td>
<td><img src="Tumor_Day35.png" alt="Image" /></td>
<td><img src="Tumor_HR_Day35.png" alt="Image" /></td>
<td><img src="Tumor_HM85R_Day35.png" alt="Image" /></td>
</tr>
<tr>
<td>p21</td>
<td><img src="p21_Day35.png" alt="Image" /></td>
<td><img src="p21_HR_Day35.png" alt="Image" /></td>
<td><img src="p21_HM85R_Day35.png" alt="Image" /></td>
</tr>
</tbody>
</table>
Clinical Cancer Research

Anti-Tumor Activity of Cell-Permeable RUNX3 Protein in Gastric Cancer Cells

Junghee Lim, Tam Duong, Nga Do, et al.

Clin Cancer Res Published OnlineFirst December 10, 2012.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-12-2692

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2012/12/10/1078-0432.CCR-12-2692.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.